Viewing Study NCT00005959


Ignite Creation Date: 2025-12-24 @ 3:05 PM
Ignite Modification Date: 2026-02-10 @ 1:16 AM
Study NCT ID: NCT00005959
Status: UNKNOWN
Last Update Posted: 2013-12-04
First Post: 2000-07-05
Is Gene Therapy: True
Has Adverse Events: False

Brief Title: Combination Chemotherapy Plus Rituximab in Treating Patients With Intermediate-Grade or High-Grade Non-Hodgkin's Lymphoma
Sponsor: Amgen
Organization:

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Lymphoma View
Keywords:

Keywords

Keyword Brief Keyword Text View
None stage III grade 3 follicular lymphoma View
None stage III adult diffuse small cleaved cell lymphoma View
None stage III adult diffuse mixed cell lymphoma View
None stage III adult diffuse large cell lymphoma View
None stage III adult immunoblastic large cell lymphoma View
None stage III adult Burkitt lymphoma View
None stage IV grade 3 follicular lymphoma View
None stage IV adult diffuse small cleaved cell lymphoma View
None stage IV adult diffuse mixed cell lymphoma View
None stage IV adult diffuse large cell lymphoma View
None stage IV adult immunoblastic large cell lymphoma View
None stage IV adult Burkitt lymphoma View
None contiguous stage II grade 3 follicular lymphoma View
None contiguous stage II adult diffuse small cleaved cell lymphoma View
None contiguous stage II adult diffuse mixed cell lymphoma View
None contiguous stage II adult immunoblastic large cell lymphoma View
None contiguous stage II adult diffuse large cell lymphoma View
None contiguous stage II adult Burkitt lymphoma View
None noncontiguous stage II grade 3 follicular lymphoma View
None noncontiguous stage II adult diffuse small cleaved cell lymphoma View
None noncontiguous stage II adult diffuse mixed cell lymphoma View
None noncontiguous stage II adult immunoblastic large cell lymphoma View
None noncontiguous stage II adult diffuse large cell lymphoma View
None noncontiguous stage II adult Burkitt lymphoma View